The Pharmacodynamic Inhibition of Estrogen Synthesis by Fadrozole, an Aromatase Inhibitor, and Its Pharmacokinetic Disposition

G. M. Kochak, S. Mangat, M. T. Mulagha, E. A. Entwistle, R. J. Santen, Allan Lipton, Laurence Demers

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

In this dose-ranging phase I study, the relationship between in vivo androgen to estrogen conversion kinetics and plasma concentrations of fadrozole was investigated in postmenopausal women receiving therapy with this aromatase inhibitor. Patients received ascending doses, ranging from 0.3–8 mg fadrozole twice daily, each for a period of 2 weeks. Drug kinetics and endocrine effects were evaluated specifically for the 2- and 8-mg twice daily treatment regimens. The in vivo activity of the drug was demonstrated by the suppression of estrone and estradiol biosynthesis from testosterone and androstenedione, respectively. The drug inhibitory constant, K1, for the estrone synthetic pathway, was 3.0 ng/mL (13.4 nmol/L) and was of similar magnitude as that determined under in vitro conditions. The K1 for the estradiol synthetic pathway was 5.3 ng/mL (23.7 nmol/L). The disparity between K1 values may indicate that the two pathways are not equivalent in terms of their inhibition by fadrozole. Pharmacokinetic data demonstrated that the drug was rapidly absorbed after oral dosing, with peak plasma concentrations achieved in median times of 1 and 2 h, respectively, for the 2- and 8-mg twice daily treatment regimens. The average half-life and oral clearance values were 10.5 h and 621 mL/min, respectively. Oral clearance was independent of dose.

Original languageEnglish (US)
Pages (from-to)1349-1355
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume71
Issue number5
DOIs
StatePublished - Jan 1 1990

Fingerprint

Fadrozole
Pharmacodynamics
Aromatase Inhibitors
Pharmacokinetics
Estrogens
Estrone
Estradiol
Pharmaceutical Preparations
Androstenedione
Plasmas
Androgens
Kinetics
Half-Life
Testosterone
Biosynthesis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Kochak, G. M. ; Mangat, S. ; Mulagha, M. T. ; Entwistle, E. A. ; Santen, R. J. ; Lipton, Allan ; Demers, Laurence. / The Pharmacodynamic Inhibition of Estrogen Synthesis by Fadrozole, an Aromatase Inhibitor, and Its Pharmacokinetic Disposition. In: Journal of Clinical Endocrinology and Metabolism. 1990 ; Vol. 71, No. 5. pp. 1349-1355.
@article{1f9d17224662499ca92729d62b5a967e,
title = "The Pharmacodynamic Inhibition of Estrogen Synthesis by Fadrozole, an Aromatase Inhibitor, and Its Pharmacokinetic Disposition",
abstract = "In this dose-ranging phase I study, the relationship between in vivo androgen to estrogen conversion kinetics and plasma concentrations of fadrozole was investigated in postmenopausal women receiving therapy with this aromatase inhibitor. Patients received ascending doses, ranging from 0.3–8 mg fadrozole twice daily, each for a period of 2 weeks. Drug kinetics and endocrine effects were evaluated specifically for the 2- and 8-mg twice daily treatment regimens. The in vivo activity of the drug was demonstrated by the suppression of estrone and estradiol biosynthesis from testosterone and androstenedione, respectively. The drug inhibitory constant, K1, for the estrone synthetic pathway, was 3.0 ng/mL (13.4 nmol/L) and was of similar magnitude as that determined under in vitro conditions. The K1 for the estradiol synthetic pathway was 5.3 ng/mL (23.7 nmol/L). The disparity between K1 values may indicate that the two pathways are not equivalent in terms of their inhibition by fadrozole. Pharmacokinetic data demonstrated that the drug was rapidly absorbed after oral dosing, with peak plasma concentrations achieved in median times of 1 and 2 h, respectively, for the 2- and 8-mg twice daily treatment regimens. The average half-life and oral clearance values were 10.5 h and 621 mL/min, respectively. Oral clearance was independent of dose.",
author = "Kochak, {G. M.} and S. Mangat and Mulagha, {M. T.} and Entwistle, {E. A.} and Santen, {R. J.} and Allan Lipton and Laurence Demers",
year = "1990",
month = "1",
day = "1",
doi = "10.1210/jcem-71-5-1349",
language = "English (US)",
volume = "71",
pages = "1349--1355",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

The Pharmacodynamic Inhibition of Estrogen Synthesis by Fadrozole, an Aromatase Inhibitor, and Its Pharmacokinetic Disposition. / Kochak, G. M.; Mangat, S.; Mulagha, M. T.; Entwistle, E. A.; Santen, R. J.; Lipton, Allan; Demers, Laurence.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 71, No. 5, 01.01.1990, p. 1349-1355.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Pharmacodynamic Inhibition of Estrogen Synthesis by Fadrozole, an Aromatase Inhibitor, and Its Pharmacokinetic Disposition

AU - Kochak, G. M.

AU - Mangat, S.

AU - Mulagha, M. T.

AU - Entwistle, E. A.

AU - Santen, R. J.

AU - Lipton, Allan

AU - Demers, Laurence

PY - 1990/1/1

Y1 - 1990/1/1

N2 - In this dose-ranging phase I study, the relationship between in vivo androgen to estrogen conversion kinetics and plasma concentrations of fadrozole was investigated in postmenopausal women receiving therapy with this aromatase inhibitor. Patients received ascending doses, ranging from 0.3–8 mg fadrozole twice daily, each for a period of 2 weeks. Drug kinetics and endocrine effects were evaluated specifically for the 2- and 8-mg twice daily treatment regimens. The in vivo activity of the drug was demonstrated by the suppression of estrone and estradiol biosynthesis from testosterone and androstenedione, respectively. The drug inhibitory constant, K1, for the estrone synthetic pathway, was 3.0 ng/mL (13.4 nmol/L) and was of similar magnitude as that determined under in vitro conditions. The K1 for the estradiol synthetic pathway was 5.3 ng/mL (23.7 nmol/L). The disparity between K1 values may indicate that the two pathways are not equivalent in terms of their inhibition by fadrozole. Pharmacokinetic data demonstrated that the drug was rapidly absorbed after oral dosing, with peak plasma concentrations achieved in median times of 1 and 2 h, respectively, for the 2- and 8-mg twice daily treatment regimens. The average half-life and oral clearance values were 10.5 h and 621 mL/min, respectively. Oral clearance was independent of dose.

AB - In this dose-ranging phase I study, the relationship between in vivo androgen to estrogen conversion kinetics and plasma concentrations of fadrozole was investigated in postmenopausal women receiving therapy with this aromatase inhibitor. Patients received ascending doses, ranging from 0.3–8 mg fadrozole twice daily, each for a period of 2 weeks. Drug kinetics and endocrine effects were evaluated specifically for the 2- and 8-mg twice daily treatment regimens. The in vivo activity of the drug was demonstrated by the suppression of estrone and estradiol biosynthesis from testosterone and androstenedione, respectively. The drug inhibitory constant, K1, for the estrone synthetic pathway, was 3.0 ng/mL (13.4 nmol/L) and was of similar magnitude as that determined under in vitro conditions. The K1 for the estradiol synthetic pathway was 5.3 ng/mL (23.7 nmol/L). The disparity between K1 values may indicate that the two pathways are not equivalent in terms of their inhibition by fadrozole. Pharmacokinetic data demonstrated that the drug was rapidly absorbed after oral dosing, with peak plasma concentrations achieved in median times of 1 and 2 h, respectively, for the 2- and 8-mg twice daily treatment regimens. The average half-life and oral clearance values were 10.5 h and 621 mL/min, respectively. Oral clearance was independent of dose.

UR - http://www.scopus.com/inward/record.url?scp=0025048116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025048116&partnerID=8YFLogxK

U2 - 10.1210/jcem-71-5-1349

DO - 10.1210/jcem-71-5-1349

M3 - Article

C2 - 2146284

AN - SCOPUS:0025048116

VL - 71

SP - 1349

EP - 1355

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -